238 related articles for article (PubMed ID: 9923536)
1. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
Ellis AG; Webster LK
Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80.
Ellis AG; Crinis NA; Webster LK
Cancer Chemother Pharmacol; 1996; 38(1):81-7. PubMed ID: 8603456
[TBL] [Abstract][Full Text] [Related]
3. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
4. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
5. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Drug Metab Dispos; 1999 Nov; 27(11):1300-5. PubMed ID: 10534315
[TBL] [Abstract][Full Text] [Related]
6. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
7. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
8. Disposition of amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
[TBL] [Abstract][Full Text] [Related]
9. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Sci; 2005 Jan; 94(1):169-76. PubMed ID: 15761940
[TBL] [Abstract][Full Text] [Related]
11. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
12. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
13. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
[TBL] [Abstract][Full Text] [Related]
14. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.
Khezrian M; Sheikholeslami B; Dadashzadeh S; Lavasani H; Rouini M
Cancer Chemother Pharmacol; 2015 May; 75(5):961-8. PubMed ID: 25757960
[TBL] [Abstract][Full Text] [Related]
17. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
18. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
19. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Kamijo Y; Ito C; Nomura M; Sai Y; Miyamoto K
Cancer Lett; 2010 Jan; 287(2):182-6. PubMed ID: 19608331
[TBL] [Abstract][Full Text] [Related]
20. The disposition of primaquine in the isolated perfused rat liver. Effect of dose size.
Ward SA; Mihaly GW; Nicholl DD; Edwards G; Breckenridge AM
Drug Metab Dispos; 1985; 13(4):425-9. PubMed ID: 2863105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
